China Accepts Telix NDA For Illuccix PSMA-PET Prostate Cancer Imaging

Telix Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for TLX591-Px (Illuccix®), a kit used to prepare ^68Ga-PSMA-11 for prostate cancer imaging. Illuccix is Telix’s lead diagnostic imaging agent for prostate cancer and represents a key step in expanding access to PSMA-PET imaging in China.